Zai Lab Limited (ZLAB)

Market Cap	2.58B
Revenue (ttm)	355.75M
Net Income (ttm)	-270.85M
Shares Out	98.44M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,322,486
Open	26.59
Previous Close	26.15
Day's Range	25.63 - 26.73
52-Week Range	13.48 - 36.60
Beta	1.04
Analysts	Strong Buy
Price Target	52.50 (+100.15%)
Earnings Date	Nov 12, 2024

About ZLAB

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia grav...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 2,175
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB
• Website: https://www.zailaboratory.com

Financial Performance

In 2023, Zai Lab's revenue was $266.72 million, an increase of 24.03% compared to the previous year's $215.04 million. Losses were -$334.62 million, -24.51% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price forecast is $52.5, which is an increase of 100.15% from the latest price.

Price Target

$52.5

(100.15% upside)

Analyst Consensus: Strong Buy